Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REIN-TX: Heterologous vs Homologous COVID-19 Booster in Transplant Patients
NCT05048940Phase 3Withdrawn
- Sponsor
- IDIVAL
- Start
- Sep 2021
- Primary completion
- Sep 2021
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19), sponsored by IDIVAL. Primary endpoint: anti-S1-RBD IgG antibodies at 28 days. Planned start Sep 2021; status: withdrawn.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05048940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048940.